Literature DB >> 6897069

Participation of cholinergic muscarinic receptors in glucagon- and arginine-mediated growth hormone secretion in man.

G Delitala, T Frulio, A Pacifico, M Maioli.   

Abstract

To investigate the participation of cholinergic receptors in glucagon- and arginine-induced GH and PRL secretion, glucagon (1 mg, sc) and arginine (30 mg over 30 min) were administered to a group of normal subjects. On a different occasion, both tests were repeated after premedication with 40 mg pirenzepine, a muscarinic blocker, given iv 5 min before the test substances. Pirenzepine completely suppressed the glucagon- and arginine-induced GH rise in all subjects. The PRL response to arginine was not altered by pirenzepine. The results suggest that cholinergic muscarinic receptors regulate the GH response to glucagon and arginine in man.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6897069     DOI: 10.1210/jcem-55-6-1231

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Clinical and pharmacological characterization of anomalous metoclopramide-induced growth hormone secretion in insulin-dependent diabetes mellitus.

Authors:  F Caviezel; G Lepore; M L Maglio; M Croci; G Comi; L Morricone
Journal:  Acta Diabetol Lat       Date:  1989 Apr-Jun

Review 2.  Neuroendocrine regulation of human growth hormone secretion. Diagnostic and clinical applications.

Authors:  G Delitala; P Tomasi; R Virdis
Journal:  J Endocrinol Invest       Date:  1988-06       Impact factor: 4.256

3.  Effects of cholinergic blockade by pirenzepine on insulin and glucose response to oral and intravenous glucose and to arginine load in obesity.

Authors:  M Maccario; S Grottoli; M Procopio; S E Oleandri; G M Boffano; P Savio; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1997-01       Impact factor: 4.256

4.  The paradoxical response of growth hormone (GH) to thyrotropin-releasing hormone (TRH) in constitutionally tall children involves a cholinergic pathway.

Authors:  E Arteaga; P Valenzuelaa; A Cattani; M del Valle
Journal:  J Endocrinol Invest       Date:  1989-09       Impact factor: 4.256

5.  Low dose orally administered arginine is able to enhance both basal and growth hormone-releasing hormone-induced growth hormone secretion in normal short children.

Authors:  J Bellone; E Bartolotta; G Cardinale; E Arvat; V Cherubini; G Aimaretti; M Maccario; M Mucci; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1993 Jul-Aug       Impact factor: 4.256

6.  A neuroendocrinological approach to evidence an impairment of central cholinergic function in aging.

Authors:  E Ghigo; S Goffi; E Arvat; E Imperiale; G M Boffano; M R Valetto; E Mazza; I Santi; A Magliona; M F Boghen
Journal:  J Endocrinol Invest       Date:  1992-10       Impact factor: 4.256

7.  Mutation analysis of the muscarinic cholinergic receptor genes in isolated growth hormone deficiency type IB.

Authors:  Ali Mohamadi; Marco Martari; Cindy D Holladay; John A Phillips; Primus E Mullis; Roberto Salvatori
Journal:  J Clin Endocrinol Metab       Date:  2009-05-05       Impact factor: 5.958

8.  Glucagon stimulates GH secretion after intramuscular but not intravenous administration. Evidence against the assumption that glucagon per se has a GH-releasing activity.

Authors:  E Ghigo; E Bartolotta; E Imperiale; J Bellone; G Cardinale; G Aimaretti; M R Valetto; V Cherubini; M Maccario; D Cocchi
Journal:  J Endocrinol Invest       Date:  1994-12       Impact factor: 4.256

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.